Spectrum says U.S. FDA declines to approve Evomela for injection
October 23, 2015 at 01:43 AM EDT
Oct 23 (Reuters) - Biotechnology company Spectrum Pharmaceuticals Inc said the U.S. Food and Drug Administration declined to approve its Evomela injection to treat patients with multiple myeloma, a form of blood cancer that arises from plasma cells found in bone marrow.
